StemXO’s current work is focused on testing exosomes, nanosized extracellular vesicles containing crucial cell-to-cell signals involved in health, growth and other metabolic functions, derived from human umbilical mesenchymal stem cells (MSCs) as potential therapeutic agents for aging-associated diseases of the central nervous system.
A growing body of evidence is demonstrating that adult stem cells play a critical role in preventing chronic elevations in inflammation, and that their depletion with aging is associated with the coincidental rise in a variety of inflammatory disease states. It has also been found that exosomes secreted by these stem cells play a key role in mediating this protective effect. An increasing number of studies in parallel are also demonstrating the therapeutic efficacy of exosomes derived from a variety of cell types in reducing inflammation and promoting endogenous mechanisms of healing in response to injury in multiple tissues including brain. MSCs are being given particular attention due to the relative ease of obtaining purified exosomes in large numbers and their demonstrated efficacy in a number of therapeutic applications.
Meet the StemXO Advisory Team
Ranbir Sahni, CEO. Mr. Sahni has decades of experience in innovative leadership as the CEO of companies that have overseen the development of clean energy technology including real estate ,wind, solar and ethanol since 1985 when he was named the 7th builder in USA by professional Builder In recent years he has extended this experience to technology see robowind.com (robot to replace labor for maintaining turbine blades aloft),Microgrid.tech to build microgrids with solar batteries and CHP in PR. Also built LCD manufacturing for replacement of broken screens for smart phones for creating jobs in PR. Recently he has invested in biomedical research, and through his work with StemXo in treating Hypothalamus inflammation with exosomes and development of new cures for devastating diseases to improve the quality of life of elderly people.
Ranbir Sahni, migrated to the US in 1968, having left his career in the Indian Air Force as a top gun instructor. After flying for TWA for couple of years , he started his own real estate company in 1972 with a capital of $32,000 with no experience or education in Real estate and grew the company to a billion dollar business by 1985
In 1985 he was ranked 7th homebuilder in USA by Professional Builder magazine and the No 4 apartment builder in the USA, with a turnover of volume of $880 Million that year. During his real estate career he has built 16,000 apartments and thousands of homes and Condos in 17 US states out of which 8500 apartments were the low income housing in depressed localities. He also built commercial projects shopping projects and hotels during his in carreer of 13 years as builder he built real estate with total value 2 billion dollars .
He has decades of experience as the CEO of several companies involved in innovative technology projects. These include the development of several clean energy technologies which among other things comprise of wind farms with capacity of 15 MW, solar projects consisting of 5 MW of PV and3000 apartments were fitted with thermal solar. He also built 2 ethanol plants in Iowa and Nebraska in 1985.
In recent years he has extended his entrepreneurial experience to technology companies: For example, Robowind.com started in late 2017 has developed 2nd prototype of a robot which will replace highly trained and expensive labor required to maintain turbine blades aloft additionally a simple simple to install technology patented by Robowind which when installed by the robot will enhance electric production by 6-7% for each wind turbine).The maintenance of a turbine aloft costs $8000-14000 depending on size and whether it is on shore or offshore. Generally, it takes 2-3 days to do the maintenance on each turbine while the maintenance cost by robot will be substantially less and much quicker. This will increase the availability of the turbine for2 or more additional days and thus increase the production of electricity substantially.
He has established a new renewable energy company Microgrid.tech that will build microgrids with solar batteries and CHP in Puerto Rico and California, and provide the property owner a reduction of 10% in electricity rate in comparison to present utility charges. In addition, it will provide additional reliability in energy system.
Sahni has also built a semiautomatic LCD manufacturing factory in Puerto Rico for replacement of broken screens for smart phonesto export world wide
Recently, he has started biomedical research company StemXO which is working on reducing hypothalamus inflammation via exosomes using an internasal technique. StemXowill start patient trials in next couple of months which will lead to new treatments for several devastating diseases and to improve the quality of life of the elderly.
Dr. Chitra Bhakta, M.D. Family Practitioner, OC Integrative Care. An ILADS and DAN! Autism Physician specializing in autism, PANDAS, CFIDS, Lyme Disease, Fibromyalgia and autoimmune disorders, Dr. Bhakta is also a collaborator in autoimmune research at UC Irvine and has over 25 years of experience as a practicing physician.
Dr. Jayakumar Rajadas, Ph.D. Professor of biomedical engineering, Stanford University. director of the Stanford Biomaterials and Advanced Drug Delivery Laboratory.
Dr. Nitin Shah, M.D. Chief of surgical ICU, Long Beach Veterans Healthcare. An anesthesiologist, critical care specialist, and professor of anesthesiology at Loma Linda University, Dr. Shah has over 20 years of experience as a practicing physician. He has led numerous clinical trials and participated in surgical missions around the globe.
Dr. Jonathon Lakey, Ph.D. Professor of biomedical engineering, Henri Samueli School of Engineering, UC Irvine. The director of the UC Irvine School of Medicine’s Clinical Islet Program, Dr. Lakey is the co-founder of the Edmonton Protocol for pancreatic islet cell transplantation.
Dr. Sharmila Venugopal, Ph.D. Professor of Integrative Biology and Physiology, UCLA. Dr. Venugopal is an investigator and lecturer with a focus on computational neuroscience and neurodegenerative diseases.
Dr. Bobby Mehta, Ph.D. Agri & Bio Engg. Former president of the technology division of a large American Diversified Co.& Founder and CEO of Executive Cardiac Care Co. Dr. Mehta’s background includes the development of ethylene, polyethylene, ethanol, Collagen plants and many diverse technologies including Enhanced External Counter-pulsation for treating coronary artery disease patients. Involved in developing genetics, stem cell and exosomes based therapies.
Dr. Christopher Cox, Ph.D. A consultant for StemXo, Dr. Cox has conducted published biomedical research in areas ranging from neurotrauma to brain cancer at institutions including UC Davis and UCLA. He has also conducted research collaborations with private biomarker companies, and even the Department of Defense.